Amorfix and QED hook up for antibodies against cancer
This article was originally published in Scrip
Executive Summary
Amorfix Life Sciences, a Canadian company developing therapeutics and diagnostics for diseases caused by aggregates of misfolded proteins, such as cancers, amyloid lateral sclerosis and Alzheimer's disease, has signed an agreement with QED Bioscience to develop high-affinity monoclonal antibodies against a number of cancer targets.